share_log

Invivyd | 8-K: Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights

SEC ·  May 10, 2024 04:16

Summary by Moomoo AI

On May 9, 2024, Invivyd, Inc., a biopharmaceutical company, announced its financial results for the first quarter ended March 31, 2024, and provided an update on recent business highlights. The company reported a cash and cash equivalents balance of $189.4 million and expects to end the year with at least $75 million, based on projected net product revenue of $150-$200 million. Invivyd launched PEMGARDA in the U.S. for COVID-19 pre-exposure prophylaxis in certain immunocompromised adults and adolescents, following its emergency use authorization by the FDA on March 22, 2024. The company also received reimbursement codes from CMS, covering approximately half of the target population for PEMGARDA. Additionally, Invivyd plans to submit an EUA application for COVID-19 treatment in certain immunocompromised individuals, based on FDA feedback. The company...Show More
On May 9, 2024, Invivyd, Inc., a biopharmaceutical company, announced its financial results for the first quarter ended March 31, 2024, and provided an update on recent business highlights. The company reported a cash and cash equivalents balance of $189.4 million and expects to end the year with at least $75 million, based on projected net product revenue of $150-$200 million. Invivyd launched PEMGARDA in the U.S. for COVID-19 pre-exposure prophylaxis in certain immunocompromised adults and adolescents, following its emergency use authorization by the FDA on March 22, 2024. The company also received reimbursement codes from CMS, covering approximately half of the target population for PEMGARDA. Additionally, Invivyd plans to submit an EUA application for COVID-19 treatment in certain immunocompromised individuals, based on FDA feedback. The company is advancing its next monoclonal antibody candidate, VYD2311, engineered with advanced technologies for variant monitoring and antibody engineering. Research and development expenses for the quarter were $31.2 million, and selling, general, and administrative expenses were $14.9 million. The net loss for the quarter was $43.5 million, with a net loss per share of $0.38. Invivyd will host a conference call to discuss these updates.

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated